Clinical Trials Using Fludeoxyglucose F-18

Clinical trials are research studies that involve people. The clinical trials on this list are studying Fludeoxyglucose F-18. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 45
1 2 Next >

  • Pembrolizumab and Involved Site Radiation Therapy in Treating Patients with Early Stage Relapsed or Refractory Hodgkin Lymphoma

    This phase II trial studies how well pembrolizumab and involved site radiation therapy works in treating patients with early stage Hodgkin lymphoma that has come back after a period of improvement or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Involved site radiotherapy is a more targeted form of radiation therapy which uses imaging studies such as computerized tomography and positron emission tomography scans to limit the dose and field of radiation administered in order to limit undesirable side effects. Giving pembrolizumab and involved site radiation therapy may improve the ability of T cells to recognize and fight off cancer cells.
    Location: 8 locations

  • Carboplatin, Paclitaxel, Radiation Therapy, and FDG-PET / CT in Treating Patients with P16 or HPV Positive Oropharyngeal Squamous Cell Carcinoma

    The purpose of this phase II trial is to see if pre-treatment and mid-treatment positron emission tomography (PET) / computed tomography (CT) can be used to guide the amount of radiation therapy given in combination with chemotherapy to patients with human papillomavirus (HPV) related squamous cell carcinoma of the oropharynx. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Diagnostic procedures, such as PET / CT, uses radioactive material, such as fludeoxyglucose F-18 (FDG), injected into the blood to show the internal workings of the body and may help the doctors understand the exact location of the disease. Giving carboplatin, paclitaxel, radiation therapy, and FDG-PET / CT may work better in treating patients with oropharyngeal squamous cell carcinoma.
    Location: 2 locations

  • C11-AMT PET Imaging in Predicting Tumor Response to Pembrolizumab in Patients with Metastatic Melanoma

    This phase II trial studies how well carbon C 11 alpha-methyltryptophan (C11-AMT) positron emission tomography (PET) imaging works in predicting tumor response to pembrolizumab in patients with melanoma that has spread to other parts of the body. C11-AMT PET imaging may be a less invasive way to predict tumor response to pembrolizumab.
    Location: 2 locations

  • FLARE RT for Patients with Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET / CT and SPECT / CT Imaging

    This phase II trial studies how well positron emission tomography (PET) / computed tomography (CT) and single positron emission computed tomography (SPECT) / CT imaging works in improving radiation therapy treatment in patients with stage IIB-IIIB non-small cell lung cancer. PET / CT imaging mid-way through treatment may be able to accurately show how well radiation therapy and chemotherapy are working. SPECT / CT imaging may be able to tell which parts of the lung tissue are healthier than others. Based on the result of the imaging, treatment adjustments may be made to the radiation therapy to improve survival and decrease toxicity.
    Location: 2 locations

  • FDG-PET and V / Q SPECT-Guided Radiation Therapy in Treating Patients with Stage IIA-IIIB Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

    This pilot trial studies fludeoxyglucose F 18–positron emission tomography (FDG-PET) and ventilation / perfusion single photon emission computed tomography (V / Q SPECT), before treatment and then again during radiation therapy in treating patients with stage IIA-IIIB non-small cell lung cancer (NSCLC) that cannot be removed by surgery. Diagnostic procedures, such as FDG-PET, uses small amounts of radioactive glucose (FDG) to make images of the whole body and areas of active cancer. V / Q SPECT is an image mapping tool that helps find out how well the lungs are working and where the cancer or healthy lung is located. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Imaging studies such as FDG-PET and V / Q SPECT may help researchers design radiation treatment plans that help decrease the amount of toxicity patients have from this type of treatment and provide the best treatment.
    Location: 2 locations

  • Image-Guided Cryoablation in Treating Patients with Head, Neck, and Spine Tumors

    This phase I clinical trial studies image-guided cryosurgery in treating patients with head, neck, and spine tumors. Cryoablation, also known as cryosurgery, is a procedure in which an extremely cold liquid or an instrument called a cryoprobe is used to freeze and destroy abnormal tissue. Cryoablation may shrink the tumor, reduce pain, and improve quality of life in patients with head, neck, and spine tumors.
    Location: 2 locations

  • Fluorine F 18 Fluorthanatrace PET / CT in Treating Patients with Primary or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET) / computed tomography (CT) works in treating patients ovarian, fallopian tube, or primary peritoneal cancer that is primary or has come back. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET / CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET / CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma / Paraganglioma

    Background: Pheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region. Not all these tumors can be removed with surgery, and there are no good treatments if the disease has spread. Researchers think a new drug may be able to help. Objective: To learn the safety and tolerability of Lu-177-DOTATATE. Also, to see if it improves the length of time it takes for the cancer to return. Eligibility: Adults who have an inoperable tumor of the study cancer that can be detected with Ga-68-DOTATATE PET / CT imaging Design: Participants will be screened with a medical history, physical exam, and blood tests. Eligible participants will be admitted to the NIH Clinical Center. Participants will get the study drug in an intravenous infusion. They will get 4 doses, given about 8 weeks apart. Between 4 and 24 hours after each study drug dose, participants will have scans taken. They will lie on their back on a scanner table. Participants will have vital signs taken. They will give blood and urine samples. During the study, participants will have other scans taken. Some scans will use a radioactive tracer. Participants will complete quality of life questionnaires. Participants will be contacted by phone 1-3 days after they leave the Clinical Center. They will then be followed every 3 to 6 months for 3 years or until their disease gets worse.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Gene and Vaccine Therapy in Treating Patients with Advanced Malignancies

    This phase IIa trial studies how well gene therapy and vaccine therapy work in treating patients with cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) undergoing stem cell transplant. Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill cancer cells. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Stereotactic Radiation Therapy in Treating Patients with Liver Metastases

    This phase I trial studies the side effects and the best dose of stereotactic radiation therapy in treating patients with liver metastases. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

    Background: A neuroendocrine tumor is a rare type of tumor. It comes from body cells called neuroendocrine cells. Sometimes, these tumors develop in the gastrointestinal tract and pancreas. Researchers want to find out if a combination of drugs can shrink these tumors. Objective: To learn if people with certain neuroendocrine tumors can take a combination of 2 drugs, Lutathera and Olaparib, without having severe side effects, and if this treatment makes the tumors shrink. Eligibility: Adults 18 and older who have a neuroendocrine tumor in the pancreas or intestine that cannot be cured by surgery and has somatostatin receptors on the cells. Design: Participants will be screened under protocol 01-C-0129. They may have a tumor biopsy. Eligible participants will get Lutathera through an intravenous (IV) infusion every 8 weeks for 4 cycles. One cycle is 8 weeks. Each cycle includes a follow-up visit at week 4. For the IV, a small plastic tube is put into an arm vein. Participants will also take Olaparib by mouth twice a day for 4 weeks of each cycle. They will use a medicine diary to track the doses. During the study, participants will have physical exams. They will have blood and urine tests. They will fill out questionnaires about their general well-being and function. Their heart function will be tested. They will have scans of their chest, abdomen, and pelvis. One type of scan will use an IV infusion of a radioactive tracer. Participants will have a follow-up visit about 4 weeks after treatment ends. Then they will have follow-up visits every 12 weeks for 3 years. Then they will have yearly phone calls....
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

    This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated recurrent glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in tumor glucose utilization, which may allow investigators to obtain an early read out on the impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.
    Location: Mayo Clinic, Rochester, Minnesota

  • 18F-FBnTP Positron Emission Mammography in Detecting Breast Cancer in Patients with Intraductal Breast Cancer

    This phase I trial studies how well 18F-FBnTP positron emission mammography works in detecting breast cancer in patients with intraductal breast cancer. 18F-FBnTP positron emission mammography may detect may detect breast lesions with better sensitivity and better specificity.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • 18F-FDG PET / CT before Surgery in Mapping Lymph Nodes in Patients with Stage IB Cervical Cancer or High-Grade Endometrial Cancer

    This pilot phase I trial studies fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) / computed tomography (CT) before surgery in mapping lymph nodes in patients with stage IB cervical cancer or endometrial cancer that grows and spreads quickly (high-grade). Lymph nodes are linked together by vessels called lymphatic channels and they also contribute to tumor spreading from one lymph node to another. 18F-FDG is a radioactive substance that is injected into the cervix and is taken up by cancer cells making them light up during PET / CT scan. 18F-FDG PET / CT may show more clearly which lymph nodes in the pelvis contain tumor cells and need to be removed during surgery.
    Location: 7 locations

  • MRI Perfusion Compared to FDG PET / CT in Distinguishing between Radiation Injury and Tumor Progression in Patients with Cancer in the Brain Treated with Radiation Therapy

    This clinical trial compares magnetic resonance imaging (MRI) perfusion to fludeoxyglucose F 18 (FDG) positron emission tomography (PET) / computed tomography (CT) to see how well they work in identifying the difference between brain damage caused by radiation therapy and tumor growth in patients who have received radiation therapy to the brain for a brain tumor or cancer that has spread from another part of the body. MRI perfusion uses an injected dye to study the blood vessels in the tumor. FDG PET / CT combines PET and CT scans to study how quickly tumor cells are growing. It is not yet known whether MRI perfusion or FDG PET / CT is more effective at distinguishing between brain damage and tumor growth.
    Location: 6 locations

  • Fludeoxyglucose F-18 PET / MRI in Assessing Treatment Response in Patients with Nasopharyngeal Cancer Receiving Chemoradiotherapy

    This clinical trial studies how well fludeoxyglucose F-18 positron emission tomography (PET) / magnetic resonance imaging (MRI) works in assessing treatment response in patients with nasopharyngeal cancer who are receiving chemoradiotherapy. PET uses radiation and MRI uses magnetic fields to create images to provide us information about the structure, function, and metabolism (level of activity and use of nutrients) of different tissues in the body, and may help provide accurate assessment of treatment response.
    Location: 2 locations

  • Standard and Delayed FDG PET / CT after Chemoradiation Therapy in Assessing Patients with Metastatic Head and Neck Squamous Cell Cancer

    This trial studies how well standard and delayed fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) / computed tomography (CT) given after standard radiation and chemotherapy works in assessing patients with head and neck squamous cell cancer that has spread to other places in the body. Diagnostic procedures, such as PET / CT, use radioactive material, such as fludeoxyglucose F-18, to find and diagnose head and neck tumors and may help to find out how far the disease has spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Fludeoxyglucose F-18-PET in Planning Radiation Therapy in Patients with Early Stage Lung Cancer

    This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in patients with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread to lungs from other parts of the body. Using PET in addition to the standard computed tomography to plan radiation therapy for cancer may help doctors to maximize the dose to the cancer and minimize the dose to normal tissues.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Fludeoxyglucose F-18-PET in Planning Radiation Therapy in Participants with Cervical, Vulvar, Esophageal, or Anal Canal Cancer

    This pilot phase II trial studies how well fludeoxyglucose F-18 positron emission tomography (PET) works in planning radiation therapy in participants with cervical, vulvar, esophageal, or anal canal cancer. Using (PET) in addition to the standard computed tomography to plan radiation therapy for cancer may help doctors to maximize the dose to the cancer and minimize the dose to normal tissues.
    Location: Duke University Medical Center, Durham, North Carolina

  • 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

    Background: Prostate cancer is the second leading cause of cancer deaths in American men. Few options exist to create images of this type of cancer. Researchers think an experimental radiotracer called 18F-DCFPyL could find sites of cancer in the body. Objective: To see if 18F-DCFPyL can identify sites of prostate cancer in people with the disease. Eligibility: People ages 18 and older who have metastatic prostate cancer Design: Participants will be screened with: - Blood tests - Physical exam - Medical history Participants will be assigned to 1 of 2 groups based on their PSA. Participants will have 18F-DCFPyL injected into a vein. About 2 hours later they will have a whole-body Positron Emission Tomography / Computed Tomography (PET / CT). For the scan, they will lie on their back on the scanner table while it takes pictures of the body. This lasts about 50 minutes. On another day, participants will have 18F -NaF injected into a vein. About 1 hour later, they will have a whole-body PET / CT. Participants will be contacted 1 3 days later for follow-up. They may undergo PET / Magnetic Resonance Imaging (MRI) either after having a 18F-DCFPyL PET / CT, or in place of PET / CT imaging. A tube may be placed in the rectum. More coils may be wrapped around the outside of the pelvis. If the 18F-DCFPyL PET / CT is positive participants will be encouraged to undergo a biopsy of one of the tumors. The biopsy will be taken through a needle put through the skin into the tumor. Participants will be followed for 1 year. During this time researchers will collect information about their prostate cancer, such as PSA levels and biopsy results. About 4-6 months after scanning is completed, participants may have a tumor biopsy. The biopsy will be taken through a needle put through the skin into the tumor. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • PET / MRI in Assessing Response to Radiation Therapy in Patients with High Grade Sarcomas

    This pilot clinical trial studies positron emission tomography (PET) / magnetic resonance imaging (MRI) in assessing response to radiation therapy in patients with high grade sarcomas. PET / MRI may help doctors to better judge the extent of cancer, and in the future, may help predict which patients will benefit from radiation therapy treatments.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Fludeoxyglucose F-18 PET / CT in Measuring Response to Lenalidomide in Patients with Non-Hodgkin Lymphoma

    This pilot clinical trial studies how well fludeoxyglucose F-18 PET / CT works in measuring response to lenalidomide in patients with non-Hodgkin lymphoma. Diagnostic procedures, such as fludeoxyglucose F-18 PET / CT may help measure a patient's response to earlier treatment.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • FDG PET / CT in Monitoring Very Early Therapy Response in Patients with Glioblastoma

    This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET) / computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET / CT, may help measure a patient’s response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor’s glucose consumption which can be measured with imaging. FDG PET / CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Early FDG PET / CT Imaging in Predicting Response to Treatment with Pembrolizumab in Patients with Stages III or IV Melanoma That Can Be Removed by Surgery

    This pilot clinical trial studies how well early fluorodeoxyglucose F-18 (FDG) positron emission tomography / computed tomography (PET / CT) works in predicting response to treatment with pembrolizumab in patients with stages III or IV melanoma that can be removed by surgery. Diagnostic procedures, such as FDG PET / CT, may help predict a patient's response to therapy.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania


1 2 Next >